Oral obesity therapies market seen reaching $6.32 billion by 2030

The Business Research Company says the oral obesity therapies market will grow from $3.94 billion in 2025 to $6.32 billion by 2030, driven by rising obesity rates, oral GLP-1 adoption and new drug development. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Oral obesity therapies are becoming a bigger part of weight-management care as obesity rates rise worldwide. - The market growth reflects demand for treatments that can support appetite control, metabolism and fat absorption. - The shift could expand access to drug-based obesity care as pharmaceutical pipelines and telemedicine tools advance.

What happened: - The Business Research Company projected the oral obesity therapies market will rise from $3.94 billion in 2025 to $4.32 billion in 2026. - The company forecast the market will reach $6.32 billion by 2030. - The report put the market’s 2025-2030 CAGR at 9.9%. - The company published the forecast on July 5, 2026. - The report is available as a free sample and as the full market report.

The details: - Oral obesity therapies are medicines taken by mouth to help manage obesity. - The therapies target appetite control, metabolism or fat absorption. - The treatments can work by suppressing hunger signals in the brain, increasing feelings of fullness or limiting dietary fat absorption. - The report linked growth to oral GLP-1 therapies, more personalized metabolic treatment, telemedicine for obesity care, next-generation oral incretin drugs and higher pharmaceutical investment in obesity pipelines. - The report said rising global obesity remains a main demand driver. - The report noted obesity raises the risk of heart disease, diabetes and hypertension. - The report cited calorie-dense processed foods and sedentary lifestyles as major contributors to obesity. - The report said oral obesity medications can help regulate hunger-related hormones and limit calorie absorption. - In May 2025, the UK Office for Health Improvement and Disparities reported that in 2023-2024 overweight and obesity prevalence was higher among men at 69.7% than women at 59.2%. - The same UK data showed obesity alone was slightly more prevalent among women at 26.9% than men at 26.2%. - North America held the largest share of the oral obesity therapies market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa.

Between the lines: - The forecast suggests obesity drugs are moving from a niche treatment category toward a broader commercial market. - Oral delivery matters because it can be easier for patients to use than injectable options. - The regional split points to an established market in North America and faster adoption potential in Asia-Pacific. - The report’s focus on telemedicine and personalized care suggests obesity treatment is becoming more integrated with digital health and long-term chronic disease management.

What's next: - Pharmaceutical companies are likely to keep building obesity drug pipelines as the market expands. - Wider adoption of oral GLP-1 and incretin therapies could shape the next phase of competition. - More market activity is likely in regions with rising obesity rates and expanding healthcare access. - The Business Research Company said its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and updated trend graphics.